Close Menu
  • Home
  • Identity
  • Inventions
  • Future
  • Science
  • Startups
  • Spanish
What's Hot

Meta fixes a bug that lets users leak AI prompts and can generate content

AV Startup Pronto.ai gets off-road self-driving car rival Safeai

Mira Murati’s Thinking Machine Lab is worth $12 billion in seed round

Facebook X (Twitter) Instagram
  • Home
  • About Us
  • Advertise with Us
  • Contact Us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
  • User-Submitted Posts
Facebook X (Twitter) Instagram
Fyself News
  • Home
  • Identity
  • Inventions
  • Future
  • Science
  • Startups
  • Spanish
Fyself News
Home » Bridge between biotechnology and veterinary care for a healthier future
Inventions

Bridge between biotechnology and veterinary care for a healthier future

userBy userFebruary 21, 2025No Comments4 Mins Read
Share Facebook Twitter Pinterest Telegram LinkedIn Tumblr Email Copy Link
Follow Us
Google News Flipboard
Share
Facebook Twitter LinkedIn Pinterest Email Copy Link

Vetzigenic is transforming the treatment of challenging diseases in pets with innovative technology that produces best-in-class antibody therapies.

Vetigenix is ​​a clinical stage animal health biotechnology company dedicated to advancement in veterinary medicine with cutting-edge antibody therapies. We develop targeted treatments for companion animals for cancer and chronic diseases, and leverage our proprietary phage display technology to create safer and more effective treatments tailored to the unique biology of your pet.

Founded by experts in veterinary and human medicine, Speed ​​Genics is committed to revolutionizing pet healthcare by bringing the power of biotechnology to veterinary practice. Our innovative approach allows us to develop new treatments that improve your pet treatment outcomes and improve your veterinarian options.

Our mission

At Vettegenics, our mission is simple. It’s about ensuring your pet lives the best. We address some of the most pressing illnesses in veterinary medicine and set new standards for treatment and care. By advancing species-specific antibodies, we create treatments that maximize efficacy while minimizing side effects, ultimately improving the health of pets around the world.

Our Technology

At the heart of innovation is the Canibody™ platform, a completely dog ​​phage display library that accelerates the discovery and development of antibody tailored to pets. Unlike treatments adapted from human or mouse sources, our species-specific antibodies provide greater safety and efficacy, ensuring that your pet receives the best possible care.

Key benefits of the Canibody™ platform include:

Width and Variety: The only fully dog-derived platform featuring billions of unique antibody genes to maximize therapeutic potential. Precision targeting: A treatment designed to make the most of disease mechanisms. Improved Safety: Our antibodies, made from real dog genetic material, minimize the risks and side effects of immunogenicity. Rapid and cost-effective development: A streamlined discovery process reduces costs and drives the transition from research to clinical use.

Veterinary care

This technology provides the foundation for innovative treatment solutions and provides veterinarians with new tools to combat diseases that were previously difficult to manage.

Our Clinical Pipeline

Speed ​​is primarily focused on addressing key veterinary challenges.

Oncology

Cancer remains the leading cause of death in pets, and current treatment options are often limited in efficacy. Vetzigenic is developing a pipeline of novel immunotherapies to activate the immune system and combat cancer more effectively. Our leading candidates, VGS-001 (Anti-CCTLA4) and VGS-002 (Anti-CPD1), offer the potential to improve survival and quality of life for a variety of tumor types.

Autoimmune and chronic diseases

Beyond cancer, our research extends to antibody therapy for autoimmune and inflammatory conditions that many pets suffer from. By targeting major disease pathways, our biology may provide lasting relief and long-term health outcomes.

Our Continuous Development

Speed ​​is committed to rigorous scientific research and evidence-based development. Our portfolio includes multiple antibody candidates at different stages of research and development, with an emphasis on translation medicine to bring innovative treatments from the lab to veterinary clinics. Some areas include allergies, obesity, and feline oncology.

We are working with leading veterinary research institutes to conduct clinical trials to assess the safety and efficacy of treatments in real-world veterinary environments. Partnerships with academic institutions, CROs and veterinary oncologists ensure that they are developing treatments that meet both safety and efficacy criteria.

The future of veterinary medicine

As veterinary medicine continues to evolve, the demand for safe, effective, targeted therapies will be greater than ever. Vettgenic is at the forefront of this transformation, leveraging the power of biotechnology to develop next-generation treatments for pets.

Through continuous innovation, strategic partnerships and a steady commitment to improving pet health, we are shaping the future of veterinary medicine. Our goal is to expand the range of antibody-based therapies and enable life-saving treatments that will increase happiness and longevity everywhere for pets.

Revolutionize your pet’s health

When we blasphem, we believe that every pet deserves the best possible care. Whether you are a pet owner, veterinarian expert or researcher, we encourage you to participate in our mission to transform veterinary medicine through antibody-based therapy.

Learn more about our work, explore clinical trial opportunities, and stay up to date with the latest advances in managing the most challenging illnesses at www.vetigenics.com.

Together, your pets can live their best life.

This article will also be featured in the 21st edition of Quarterly Publication.


Source link

Follow on Google News Follow on Flipboard
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Copy Link
Previous ArticleAI Startup Figures Announce Helix: New AI Model allows robots to follow voice commands and process unknown objects
Next Article Copper Events appoint account directors
user
  • Website

Related Posts

Merger of the largest black holes detected by Ligo-Virgo-Kagra

July 15, 2025

The UK and Czech Republic establish a deal for landmark small modular reactors

July 15, 2025

The role of hybrid energy storage in the European energy transition.

July 15, 2025
Add A Comment
Leave A Reply Cancel Reply

Latest Posts

Meta fixes a bug that lets users leak AI prompts and can generate content

AV Startup Pronto.ai gets off-road self-driving car rival Safeai

Mira Murati’s Thinking Machine Lab is worth $12 billion in seed round

AI coding tools are moving to amazing locations: terminals

Trending Posts

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Please enable JavaScript in your browser to complete this form.
Loading

Welcome to Fyself News, your go-to platform for the latest in tech, startups, inventions, sustainability, and fintech! We are a passionate team of enthusiasts committed to bringing you timely, insightful, and accurate information on the most pressing developments across these industries. Whether you’re an entrepreneur, investor, or just someone curious about the future of technology and innovation, Fyself News has something for you.

ICEX Forum 2025 Opens: FySelf’s TwinH Showcases AI Innovation

The Future of Process Automation is Here: Meet TwinH

Robots Play Football in Beijing: A Glimpse into China’s Ambitious AI Future

TwinH: A New Frontier in the Pursuit of Immortality?

Facebook X (Twitter) Instagram Pinterest YouTube
  • Home
  • About Us
  • Advertise with Us
  • Contact Us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
  • User-Submitted Posts
© 2025 news.fyself. Designed by by fyself.

Type above and press Enter to search. Press Esc to cancel.